Trial Profile
An Open-Label Preoperative Pilot Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable (HCC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jul 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- 27 Apr 2023 Experimental: Arm C (ipilimumab, nivolumab) has been removed from treatments thus decreasing number of arms from 3 to 2.
- 26 Oct 2022 Status changed from active, no longer recruiting to completed.
- 26 Jul 2020 Status changed from recruiting to active, no longer recruiting.